Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMNN-001 + carboplatin + paclitaxel
- Development stage
- Unknown
- Lead developer
- IMUNON
- Modality
- Small Molecules, Gene Therapies, Nanoparticles → Drug Delivery Systems
- Administration
- Intraperitoneal, Intravenous
01
Overview
IMNN-001 + carboplatin + paclitaxel is a combination regimen under investigation for the frontline treatment of newly diagnosed advanced epithelial ovarian cancer. IMNN-001 is a nanoparticle-based DNA plasmid gene therapy encoding interleukin-12 (IL-12), delivered intraperitoneally to stimulate local immune responses, particularly T-lymphocyte and natural killer cell activity. Carboplatin and paclitaxel are chemotherapeutic agents typically used as neoadjuvant and adjuvant chemotherapy. Clinical trials (notably, the OVATION-2 phase 1/2 study) have shown that the addition of IMNN-001 to carboplatin/paclitaxel therapy improved both progression-free survival and overall survival compared to chemotherapy alone, with a favorable safety profile. IMNN-001 is developed using the TheraPlas technology platform by Imunon and is not currently approved for commercial use. The combination is under evaluation in phase 2 clinical studies with a phase 3 trial in planning for ovarian cancer.[1][2][4][5]
- Brand names
- IMNN-001IMNN001IMNN 001
- Other names
- GEN-1GEN1GEN 1
02
Targets
DNA
Beyond the preview
Go deeper on IMNN-001 + carboplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMNN-001 + carboplatin + paclitaxel.